home / stock / sphdf / sphdf short
Short Information | Santhera Pharms Hldgs Ltd (OTCMKTS:SPHDF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 63,887 |
Total Actual Volume | 84,824 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 18 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 3,194 |
Average Short Percentage | 86.73% |
Is there a SPHDF Short Squeeze or Breakout about to happen?
See the SPHDF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
01-03-2023 | $1.2 | $1.2 | $1.2 | $1.2 | 120 | 120 | 100% |
11-24-2021 | $1.4 | $1.4 | $1.4 | $1.4 | 2,100 | 2,100 | 100% |
11-19-2021 | $1.41 | $1.41 | $1.41 | $1.41 | 14,100 | 14,100 | 100% |
10-18-2021 | $1.56 | $1.56 | $1.56 | $1.56 | 500 | 500 | 100% |
10-13-2021 | $1.53 | $1.53 | $1.53 | $1.53 | 2,000 | 2,000 | 100% |
09-27-2021 | $1.58 | $1.58 | $1.58 | $1.58 | 250 | 250 | 100% |
09-22-2021 | $1.67 | $1.67 | $1.67 | $1.67 | 500 | 600 | 120% |
09-21-2021 | $1.76 | $1.71 | $1.76 | $1.65 | 2,416 | 438 | 18.13% |
09-20-2021 | $1.95 | $2 | $2 | $1.92 | 1,658 | 1,658 | 100% |
09-08-2021 | $2.24 | $2.28 | $2.28 | $2.24 | 4,499 | 4,499 | 100% |
08-25-2021 | $2.26 | $2.34 | $2.34 | $2.26 | 1,869 | 1,000 | 53.5% |
08-24-2021 | $2.26 | $2.26 | $2.26 | $2.26 | 2,200 | 2,200 | 100% |
08-13-2021 | $2.28 | $2.28 | $2.28 | $2.28 | 24,200 | 24,200 | 100% |
08-11-2021 | $2.41 | $2.34 | $2.41 | $2.34 | 500 | 500 | 100% |
08-05-2021 | $2.45 | $2.45 | $2.45 | $2.45 | 3,277 | 3,177 | 96.95% |
08-04-2021 | $2.505 | $2.45 | $2.505 | $2.45 | 1,250 | 1,150 | 92% |
07-30-2021 | $2.55 | $2.5 | $2.55 | $2.5 | 1,167 | 650 | 55.7% |
07-28-2021 | $2.5 | $2.5 | $2.5 | $2.5 | 17,773 | 400 | 2.25% |
07-21-2021 | $2.5 | $2.5 | $2.5 | $2.5 | 2,600 | 2,500 | 96.15% |
07-19-2021 | $2.55 | $2.55 | $2.55 | $2.55 | 1,845 | 1,845 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Santhera Pharms Hldgs Ltd Company Name:
SPHDF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full R...
Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted...
AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in Germany in January 2024 by Santhera AGAMREE is the first DMD...